Research overview
NAD+: what the research shows
What is NAD+?
NAD+ (nicotinamide adenine dinucleotide, also listed in PubChem as nadide) is a coenzyme found in all living cells [1] [2]. Unlike most compounds in our catalog, it is not a peptide. It is a dinucleotide: two nucleotides, one carrying adenine and one carrying nicotinamide, joined through their phosphate groups.
NAD+ has two broad jobs in the cell. It is a carrier in reduction-oxidation (redox) reactions, alternating between its oxidized form, NAD+, and its reduced form, NADH. It is also a consumed co-substrate for several enzyme families that cleave it as part of their own reactions, including sirtuins, poly(ADP-ribose) polymerases (PARPs), and the NADase CD38 [2] [3]. Because these enzymes use NAD+ up, cells must continually resynthesize it, mainly through salvage pathways that start from nicotinamide, nicotinic acid, or nicotinamide riboside [7].
That combination, a central metabolic cofactor that is also a signaling substrate, is why NAD+ appears in so many areas of laboratory research.
| Compound class | Dinucleotide coenzyme (not a peptide) |
|---|---|
| Molecular formula | C21H27N7O14P2 |
| Molecular weight | 663.4 g/mol |
| CAS number | 53-84-9 |
| PubChem CID | 5892 |
| Other names | Nadide, nicotinamide adenine dinucleotide, beta-NAD, coenzyme I, diphosphopyridine nucleotide (PubChem synonyms) |
Biochemical roles studied
Redox chemistry
As the oxidized partner of NADH, NAD+ accepts electrons in catabolic reactions and passes them on, which places it at the center of cellular metabolic pathways [2] [3].
Synthesis through the salvage pathway
In mouse fibroblasts, a 2004 kinetic study identified nicotinamide phosphoribosyltransferase (NAMPT) as the rate-limiting enzyme of the NAD biosynthesis route that starts from nicotinamide. Raising NAMPT, but not the downstream enzyme NMNAT, increased total cellular NAD and enhanced the transcriptional regulatory activity of the sirtuin Sir2alpha, linking NAD synthesis directly to sirtuin output [14]. NAMPT inhibitors such as FK866 are, for the same reason, standard tools for depleting cellular NAD+ in experiments [7].
Mitochondrial NAD+ import
Whether mammalian mitochondria import intact NAD+ was debated for years. In 2020, two independent groups reported that the inner-membrane carrier SLC25A51 (also called MCART1) is required for it. Loss of SLC25A51 lowered mitochondrial, but not whole-cell, NAD+ and impaired mitochondrial respiration, while isolated mitochondria lacking or overexpressing the carrier showed decreased or increased NAD+ uptake [15] [16]. For experimental design, this means cytosolic and mitochondrial NAD+ pools can behave differently.
Sirtuins
A 2000 study in Nature reported that yeast and mouse Sir2 proteins are NAD-dependent histone deacetylases, which deacetylate specific lysines on histones H3 and H4. The work tied a metabolic cofactor directly to chromatin regulation and gene silencing [4]. The mammalian sirtuin family has been studied as a link between cellular NAD+ availability and gene regulation ever since [3].
PARPs and DNA repair
Poly(ADP-ribose) polymerases consume NAD+ as a co-substrate. Reviews describe NAD+ as directly and indirectly influencing DNA repair, chromatin remodeling, cellular senescence, and immune-cell function through these NAD+-consuming enzymes [3].
CD38
In a 2016 mouse study, expression and activity of the NADase CD38 increased with age, and CD38 was required for the age-related fall in tissue NAD and the associated mitochondrial dysfunction, acting at least in part through the mitochondrial sirtuin SIRT3. The authors also identified CD38 as the main enzyme degrading the precursor nicotinamide mononucleotide (NMN) in vivo [5]. A follow-up study from the same Mayo Clinic group reported that a specific small-molecule CD38 inhibitor, 78c, reversed the age-related fall in tissue NAD+ in mouse models of natural and accelerated aging, and that its effects on several metabolic and physiological parameters were lost when NAD+ synthesis was blocked [17].
SARM1 and axonal NAD+ loss
NAD+ consumption is not always regulatory housekeeping. Using purified proteins and neuronal injury models, a 2017 study showed that the TIR domain of SARM1 has its own NADase activity, cleaving NAD+ into ADP-ribose, cyclic ADP-ribose, and nicotinamide, and that this activity was required for axonal NAD+ depletion and axon degeneration after injury in cultured neurons [18].
Areas of research
Age-associated NAD+ decline in model organisms
A 2021 review in Nature Reviews Molecular Cell Biology described a gradual decline in tissue and cellular NAD+ levels with age in multiple model organisms, and summarized animal studies linking that decline to metabolic, cognitive, and muscle-related phenotypes. The same review was explicit that much remains unknown, including how NAD+ levels are regulated, how to restore them effectively, and whether doing so is safe or beneficial in people [3].
Precursor molecules in animal studies
Much of the in vivo literature works with NAD+ precursors such as NMN and nicotinamide riboside (NR) rather than NAD+ itself. A 2018 review of that animal evidence summarized studies in aged animals and animal disease models in which raising NAD+ was associated with changes in several physiological measures [6].
Cell-culture considerations
Two cell studies are useful for anyone designing NAD+ experiments. In human tumor cell lines treated with the NAMPT inhibitor FK866, low micromolar extracellular NAD+, NMN, or NR rescued cells from FK866-induced death, and the surface enzymes CD73 and CD38 had opposite roles in converting extracellular NMN into a usable precursor [7]. A 2016 study using stable isotope labels confirmed that mammalian cells converted extracellular NMN to NR before taking it up, with the kinase NRK1 rate-limiting for NAD+ synthesis from these precursors [8]. Extracellular nucleotides can therefore be processed at the cell surface before entering a cell, which affects how results with any added NAD+-related compound are interpreted.
Open research questions
- Which tissues and cell types show the steepest NAD+ decline, and why [3].
- How the balance between synthesis and consumption by CD38, PARPs, and sirtuins is set in different conditions [3] [5].
- How findings with precursors relate to experiments that supply NAD+ directly [6] [8].
- How cytosolic, nuclear, and mitochondrial NAD+ pools are kept in balance, given a dedicated mitochondrial carrier [15] [16].
Considerations for experimental design
The studies above point to several practical questions a laboratory should settle before interpreting an NAD+ experiment:
- Where is the NAD+ going? Cell-surface enzymes such as CD73 and CD38 process extracellular NAD+-related nucleotides, and precursors like NMN were converted to NR before uptake in labeled-isotope experiments [7] [8]. Measuring intracellular NAD+ directly, rather than assuming it rose, avoids a common blind spot.
- Which compartment matters? Because mitochondrial NAD+ depends on the SLC25A51 carrier, whole-cell measurements can miss changes in the mitochondrial pool, and the reverse [15] [16].
- Which consumers are active? CD38, PARPs, sirtuins, and SARM1 all cleave NAD+, and their relative activity differs by cell type and stress [3] [5] [18]. Specific inhibitors, such as the CD38 inhibitor 78c in mouse work, are one way to separate them [17].
- Is synthesis the bottleneck? NAMPT limits the salvage route in mouse fibroblasts, and NAMPT inhibition with FK866 is a standard way to create an NAD+-depleted baseline against which added NAD+ or precursors can be tested [7] [14].
For the same reason, it is worth checking the lot-level identity and purity data described under testing below before an experiment starts.
Research-grade NAD+ versus supplement products
NAD+ and related molecules are also sold in consumer dietary supplement products. Those products sit in a different regulatory category. FDA states that dietary supplement firms are responsible for evaluating the safety and labeling of their products before marketing [11]; FDA does not approve them as drugs.
Rejuvatide NAD+ is a research-grade reagent supplied for in vitro and laboratory use. It is not a dietary supplement, is not intended for clinic or wellness use, and nothing on this page describes or implies use in people. Its value to a laboratory is the lot-level documentation of identity and purity described below.
State of the human evidence
Clinical research on NAD+ biology is still early. A 2020 systematic review found that, despite decades of investigation, only a small number of randomized and adequately powered clinical trials of raising NAD levels had been carried out, and concluded that further trials were needed [9]. A 2024 systematic review of randomized trials included 10 studies with 489 participants that examined NADH and NAD+ precursors across several clinical conditions, and concluded that further investigation was needed [10].
Findings in model organisms and cultured cells should not be read as evidence of safety or benefit in people.
Regulatory status
- Not an FDA-approved drug. No drug application for NAD+ (nadide) appears in FDA's Drugs@FDA database, as checked on October 12, 2026 [12].
- Not a supplement here. Products marketed as dietary supplements are regulated differently, as described above [11]. This product is not one of them.
- Sport. NAD+ is not named on the World Anti-Doping Agency's 2026 Prohibited List [13]. WADA advises checking with an anti-doping organization about any substance not listed.
Rejuvatide supplies NAD+ strictly as a research chemical for in vitro and laboratory use. It is not sold for human or veterinary use.
Testing and quality
Every Rejuvatide lot of NAD+ is tested by an independent laboratory for purity by HPLC and identity by LC-MS, and the lot also carries an endotoxin certificate. The current certificates are shown below and in our COA library, where you can match the lot number on your vial to its report. Certificates are published exactly as the laboratory issued them.
Related research compounds include MOTS-c and SS-31. Browse all related research compounds, or see our FAQ for ordering questions.
Storage of the sealed vial
NAD+ ships as a dry powder. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.